Animal models and related services (AMRS) core

动物模型和相关服务（AMRS）核心 动物模型和相关服务（AMRS）核心3的总体目标是建立生物防护 致力于开发BSL 3病原体动物模型和相关支持的研究支持服务核心 服务核心3与罗格斯大学研究项目的基础和翻译焦点高度相关。没有 动物模型完美地再现了人类对感染的反应。因此，在核心3中， 开发不同的动物模型，可用于解决与呼吸道病原体相关的特定方面- 诱发疾病。新开发的动物模型，以及RBL研究人员随后使用它们， AMRS核心支持，沿着购买额外的专业设备，将支持和加强 罗格斯大学的研究人员探索病原体感染和传播的各个方面， 和宿主疾病的发病机制。随着SARS-CoV-2从大流行性病毒转变为地方性病毒， 变异体继续以较高的传播率出现，这似乎与较低的致病性相关。 AIM 1将开发用于研究SARS-CoV-2传播性的动物模型。已经有五个IAV 自1900年代以来，H5N1流感大流行，人们一直担心目前爆发的高致病性H5N1 禽流感病毒迄今已感染了5000多万只禽类，它可能会传染给人类， 新的流行病。将建立动物模型来研究IAV在AIM 2中的传播。一部分人 COVID-19后的长期并发症，称为COVID-19后急性后遗症（PASC）。在aim中 3、建立仓鼠PASC模型。雪貂的呼吸道与 人类和雪貂对M.结核病（Mtb）和几种人类呼吸道病毒。 因此，我们在目标4中建议开发一个雪貂传播模型，并测试其是否适用于调查 Mtb临床菌株的遗传性，以及鉴定Mtb在连续的 与传输相关的压力。超过一半的结核病患者通过微生物学方法治愈， (TB)肺结核后表现出某种形式的肺损伤（PIAT），影响长期呼吸系统健康。在目标5中， 我们将建立一个肺结核后肺损害的临床前小鼠模型（PIAT），用于评估辅助宿主 定向治疗动物模型的建立以测试新发现的具有抗肿瘤活性的化合物的功效 体外结核活性将大大推进结核药物计划。在目标6中，我们将建立临床前 用于新的结核病候选药物的功效测试的鼠模型。随着这六个目标的实现， 核心的技术人员将帮助RBL研究人员在这些动物模型的性能在自己的赠款 支持研究。实现这些目标所需的人员、仪器和经验也将 根据需要开发和支持更多的动物模型，以应对新的生物威胁、流行病 或新出现的传染病

ABSTRACT Animal Models and Related Services (AMRS) Core The overall goal of Animal Models and Related Services (AMRS) Core 3 is to establish a biocontainment research support service core devoted to developing animal models of BSL3 pathogens and associated support services. Core 3 is highly relevant to the basic and translational foci of the research programs at Rutgers. No animal model perfectly reproduces the response to infection seen in humans. In Core 3, we are therefore developing different animal models that can be used to address specific aspects related to respiratory pathogen- induced disease. The newly developed animal models, and their subsequent use by RBL investigators with AMRS Core support, along with the purchase of additional specialized equipment will support and enhance the research enterprise of Rutgers investigators exploring various aspects of pathogen infection and transmission, and host disease pathogenesis. As SARS-CoV-2 transitions from a pandemic virus to an endemic one, new variants continue to appear with higher transmission rates which appear to correlate with lower pathogenicity. AIM 1 will develop animal models for investigating transmissibility of SARS-CoV-2. There have been five IAV pandemics since the 1900s, and there is ongoing concern that the current outbreak of high pathogenic H5N1 avian Influenza virus, which has affected more than 50 million birds so far, could jump to humans and cause a new pandemic. Animal models will be devloped to study IAV transmission in AIM 2. A subset of individuals has prolonged complications after COVID-19, which is known as post-acute sequalae of COVID-19 (PASC). In Aim 3, we will develop the hamster model to study PASC. The ferret respiratory tract has several similarities to humans and ferrets are highly permissive to M. tuberculosis (Mtb) and several human respiratory viruses. Therefore, we propose in Aim 4 to develop a ferret transmission model and test its suitability for investigating transmissibility of clinical strains of Mtb and in identifying the genes that Mtb requires to survive the successive stresses associated with transmission. More than half of the people with microbiologically cured tuberculosis (TB) exhibit some form of pulmonary impairment after TB (PIAT) affecting long-term respiratory health. In Aim 5, we will develop a pre-clinical mouse model of pulmonary impairment after TB (PIAT) for evaluating adjunct host directed therapeutics. Establishment of animal models to test efficacy of newly discovered compounds with anti- TB activity in vitro would significantly advance the TB drug program. In Aim 6, we will stablish a pre-clinical murine model for efficacy testing of new TB drug candidates. As each of these six aims are completed, the AMRS Core’s technical staff will then aid RBL investigators in the performance of these animal models in their own grant supported research. The personnel, instrumentation and experience acquired achieving these aims will also be harnessed to develop and support additional animal models as required to address new biothreats, pandemics or emerging infectious diseases.